118 related articles for article (PubMed ID: 18020978)
1. Molecular prognostic factors in patients with pancreatic cancer.
Tonini G; Pantano F; Vincenzi B; Gabbrielli A; Coppola R; Santini D
Expert Opin Ther Targets; 2007 Dec; 11(12):1553-69. PubMed ID: 18020978
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
Ansari D; Rosendahl A; Elebro J; Andersson R
Br J Surg; 2011 Aug; 98(8):1041-55. PubMed ID: 21644238
[TBL] [Abstract][Full Text] [Related]
3. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Niedergethmann M; Hildenbrand R; Wolf G; Verbeke CS; Richter A; Post S
Int J Pancreatol; 2000 Aug; 28(1):31-9. PubMed ID: 11185708
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in pancreatic ductal adenocarcinoma.
Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
9. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer.
Kim S; Kang M; Lee S; Bae S; Han S; Jang JY; Park T
Biomed Eng Online; 2014; 13 Suppl 2(Suppl 2):S5. PubMed ID: 25560450
[TBL] [Abstract][Full Text] [Related]
10. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
11. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
Duffy MJ; Sturgeon C; Lamerz R; Haglund C; Holubec VL; Klapdor R; Nicolini A; Topolcan O; Heinemann V
Ann Oncol; 2010 Mar; 21(3):441-447. PubMed ID: 19690057
[TBL] [Abstract][Full Text] [Related]
14. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
15. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.
Coleman O; Henry M; McVey G; Clynes M; Moriarty M; Meleady P
Expert Rev Proteomics; 2016; 13(4):383-94. PubMed ID: 26985644
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis.
Perini MV; Montagnini AL; Coudry R; Patzina R; Penteado S; Abdo EE; Diniz A; Jukemura J; da Cunha JE
ANZ J Surg; 2015 Mar; 85(3):174-8. PubMed ID: 24112413
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers of early pancreatic cancer.
Goggins M
J Clin Oncol; 2005 Jul; 23(20):4524-31. PubMed ID: 16002843
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
